MSF's publications are an expression of our belief in the principle of témoignage, or bearing witness, and the belief that we are accountable to those we work for and with. Sharing news about our activities and reflecting on them, offering critiques when necessary, are therefore crucial aspects of our work.

View and download these publications below.

To view the U.S. Annual Reports or International Activity Reports, please visit the Annual Reports page.

Country/Region

November 14, 2017

Ministers from the eleven countries assessing the Trans-Pacific Partnership (TPP) trade deal have suspended many of the damaging provisions that would have restricted access to medicines and vaccines, a victory for millions of people who rely on affordable medicines worldwide.

May 26, 2016

New York/Ise-Shima/Geneva—As the leaders of the G7 countries gather in Ise-Shima, Japan over the next two days, the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) is urging them to make a bold commitment to prioritize a better global response to public health emergencies and to take action to encourage the research and development (R&D) and affordable pricing of critical medicines.

April 21, 2016

The earthquakes that ratted southwestern Japan last week injured around 1,100 people in Kumamoto and Oita prefectures and led to the deaths of another 58. Roughly 103,000 people remained displaced in Kumamoto and around 600 in Oita, and the authorities are still searching for people who are unaccounted for as well. What's more, due to heavy rains and the subsequent risk of landslides, some 240,000 people have been advised to evacuate 19 cities, towns and villages in Kumamoto and Oita.

March 21, 2016

New York/Geneva, March 21, 2016—Two years after two new drugs to treat tuberculosis (TB)—the first in over 50 years—were conditionally approved for use, only two percent of the 150,000 people who need them most have been able to access them, according to Doctors Without Borders’ new edition of DR-TB Drugs Under the Microscope.

February 24, 2016

International medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) today expressed great concern at the high price announced for the new tuberculosis (TB) drug delamanid. Japanese pharmaceutical company Otsuka said that it would make delamanid available to some developing countries at a price of $1,700 per treatment course.

December 17, 2013

Tuberculosis (TB) and its drug-resistant forms are a global health threat to which children are particularly vulnerable.

May 05, 2013

A mobile MSF TB surgery mission has successfully completed surgery on six DR-TB patients in Yeravan, Armenia.

March 15, 2012

As TB cases in Armenia rise at an alarming pace, MSF is stepping up "patient-centered" treatment of the deadly disease.

Pages

November 14, 2017

Ministers from the eleven countries assessing the Trans-Pacific Partnership (TPP) trade deal have suspended many of the damaging provisions that would have restricted access to medicines and vaccines, a victory for millions of people who rely on affordable medicines worldwide.

May 26, 2016

New York/Ise-Shima/Geneva—As the leaders of the G7 countries gather in Ise-Shima, Japan over the next two days, the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) is urging them to make a bold commitment to prioritize a better global response to public health emergencies and to take action to encourage the research and development (R&D) and affordable pricing of critical medicines.

April 21, 2016

The earthquakes that ratted southwestern Japan last week injured around 1,100 people in Kumamoto and Oita prefectures and led to the deaths of another 58. Roughly 103,000 people remained displaced in Kumamoto and around 600 in Oita, and the authorities are still searching for people who are unaccounted for as well. What's more, due to heavy rains and the subsequent risk of landslides, some 240,000 people have been advised to evacuate 19 cities, towns and villages in Kumamoto and Oita.

March 21, 2016

New York/Geneva, March 21, 2016—Two years after two new drugs to treat tuberculosis (TB)—the first in over 50 years—were conditionally approved for use, only two percent of the 150,000 people who need them most have been able to access them, according to Doctors Without Borders’ new edition of DR-TB Drugs Under the Microscope.

February 24, 2016

International medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) today expressed great concern at the high price announced for the new tuberculosis (TB) drug delamanid. Japanese pharmaceutical company Otsuka said that it would make delamanid available to some developing countries at a price of $1,700 per treatment course.

December 17, 2013

Tuberculosis (TB) and its drug-resistant forms are a global health threat to which children are particularly vulnerable.

May 05, 2013

A mobile MSF TB surgery mission has successfully completed surgery on six DR-TB patients in Yeravan, Armenia.

March 15, 2012

As TB cases in Armenia rise at an alarming pace, MSF is stepping up "patient-centered" treatment of the deadly disease.

Pages